Altium Capital Management »

Sagimet Biosciences Inc-a shares owned by Altium Capital Management

Quarter-by-quarter ownership of Sagimet Biosciences Inc-a (SGMT) shares owned by Altium Capital Management from 13F filings

Historical chart of Altium Capital Management investment in Sagimet Biosciences Inc-a

Tip: Access up to 7 years of quarterly data

All positions including Sagimet Biosciences Inc-a held by Altium Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sagimet Biosciences Inc-a by Altium Capital Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $4.3M 483k 8.80

More positions owned by Altium Capital Management

Cymabay Therapeutics
Immunovant Put Put Option
ImmunoGen
Astria Therapeutics (ATXS)
Xtant Med Hldgs Com New (XTNT)
Amylyx Pharmaceuticals (AMLX)
Adma Biologics (ADMA)
Alimera Sciences Com New (ALIM)
Structure Therapeutics Sponsored Ads (GPCR)
Crinetics Pharmaceuticals In (CRNX)
Xenon Pharmaceuticals (XENE)
Biohaven (BHVN)
Axsome Therapeutics (AXSM)
Karuna Therapeutics Ord
Moonlake Immunotherapeutics Class A Ord (MLTX)

View all positions for Altium Capital Management

Top funds holding Sagimet Biosciences Inc-a

NEA Management Company
Baker Bros. Advisors
Hillhouse Capital Advisors
Artal Group
Partner Fund Management
Alyeska Investment Group
Blue Owl Capital Holdings
Vanguard Group
Dumac
AlphaCentric Advisors
Federated Investors
Bank of New York Mellon
Victory Capital Management
Millennium Management
Two Sigma Investments

View all funds holding Sagimet Biosciences Inc-a